MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ACLX stock logo

ACLX

Arcellx, Inc.

$114.77
0.02
 (0.02%)
[ms_data_label text=’Delayed data’]
Exchange:  NASDAQ
Market Cap:  6.712B
Shares Outstanding:  165581
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Rami Elghandour
Full Time Employees:  163
Address: 
25 West Watkins Mill Road
Redwood City
MD
20878
US
Website:  https://arcellx.com
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company’s lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue110,319107,93622,286
Gross Profit110,319102,74815,608
EBITDA-64,145-99,061-197,969
Operating Income-89,880-137,571-253,083
Net Income-70,690-107,348-228,934

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets825,132711,327442,404
Total Liabilities339,752256,5350
Total Stockholders Equity485,380454,7920
Total Debt97,62554,0800
Cash and Cash Equivalents394,583105,6790

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow207,573-83,467-210,258
Capital Expenditure-21,428-13,434-2,327
Free Cash Flow186,145-96,901-212,585
Net Income-70,690-107,348-228,934
Net Change in Cash332,224-290,599-25,427

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)567,508.307Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)1,909,183.234Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)1,080,611.750Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-190,622.593Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-56,662.924Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-107,893.789Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)159,978.667Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)834,654.684Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)417,998.222Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)987,977.060Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)3,323,703.311Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)1,881,240.515Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)7.420Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)14.820Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)2.840Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)5Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)4Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
107.936M  ?P/S
 (TTM)
: 
301.9
?Net Income
 (TTM)
: 
-107348000  ?P/E
 (TTM)
: 
-28.3
?Enterprise Value
 (TTM)
: 
6.744B  ?EV/FCF
 (TTM)
: 
-31.72
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.55  ?ROIC
 (TTM)
: 
-0.5
?Net Debt
 (TTM)
: 
-533503000  ?Debt/Equity
 (TTM)
: 
0.24
?P/B
 (TTM)
: 
16.1  ?Current Ratio
 (TTM)
: 
4.44

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate ACLX Intrinsic Value

Common questions about ACLX valuation

Is Arcellx, Inc. (ACLX) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Arcellx, Inc. (ACLX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ACLX a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ACLX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ACLX’s P/E ratio?

You can see ACLX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ACLX?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ACLX a good long-term investment?

Whether ACLX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ACLX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

0.02
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low: 47.86   Year High: 114.94
Price Avg 50: 95.02   Price Avg 200: 79.52
Volume: 1.209M   Average Volume: 2.421M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
17-04-2026 08:30
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
Gilead Extends Tender Offer to Acquire Arcellx
01-04-2026 16:13
Gilead Extends Tender Offer to Acquire Arcellx
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
16-03-2026 19:13
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX
23-02-2026 19:21
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX
Top 2 Health Care Stocks That May Crash This Quarter
04-03-2026 08:55
Top 2 Health Care Stocks That May Crash This Quarter
Why is Arcellx stock up 80% today? Gilead's $7.8B answer
23-02-2026 08:41
Why is Arcellx stock up 80% today? Gilead's $7.8B answer

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read